Assessment first
Evidence-aware
Safety focused
Women’s Health Clinic FAQ
What is the Vaginal Health Index (VHI) score, and how do clinicians use it to grade atrophy severity?
Technical atrophy scores can sound detached from real symptoms, but they are only useful when interpreted alongside comfort, tissue appearance, urinary symptoms and safety checks.
Direct answer
The Vaginal Health Index is a structured examination score that usually grades elasticity, secretions, pH, epithelial mucosa, moisture and sometimes petechiae or tissue integrity. It helps make atrophy visible and trackable, but it should not replace the patient's symptoms or differential diagnosis.
The safest answer separates genitourinary syndrome of menopause from infection, inflammatory skin disease, ulcers, bleeding, urinary red flags and other causes before choosing treatment.
Educational only. This page is educational and does not replace individual assessment. Results vary. Not a cure.
Atrophy assessment
At a glance
These points help place the finding in clinical context.
At a glance
Clinical summary
Purpose
Objective signs support, but do not replace, symptoms.
Measures
VHI, VMI and pH answer different questions.
Limit
Scores are not always needed in routine care.
Safety
Bleeding, ulcers or infection signs need review.
Important safety note
Seek medical advice promptly for postmenopausal bleeding, bleeding after sex, ulcers, unusual discharge, fever, severe pelvic or vulval pain, urinary retention, blood in urine, recurrent infection symptoms or a lesion that does not heal.
Oestrogen
Tissue signs
Differential diagnosis
Review
Detailed answer
Detailed answer
Objective measures may help clinicians describe tissue change, but GSM is usually interpreted through symptoms, examination and exclusion of other causes.
Clinical context
VHI is an examination-based score, VMI is a cytology-based measure of epithelial maturation, and vaginal pH reflects the chemical environment.
pH
Vascularity
Safety
What changes
Objective measures may help clinicians describe tissue change, but GSM is usually interpreted through symptoms, examination and exclusion of other causes.
Why it happens
VHI is an examination-based score, VMI is a cytology-based measure of epithelial maturation, and vaginal pH reflects the chemical environment.
What it does not prove
The key clinical judgement is whether the finding fits atrophy, infection, dermatosis, trauma, medication effect or another condition.
What keeps it safe
A single score should not be used to reassure away bleeding, ulcers, severe pain, discharge or urinary red flags.
What this means in practice
A responsible page explains the tissue mechanism without making one sign or test sound diagnostic on its own.
Symptoms such as bleeding, ulcers, severe pain, discharge or urinary red flags should be routed to medical review.
Patient safety
Why this matters
Atrophy can be uncomfortable and intimate, but the clinical priority is to explain the sign clearly without missing other causes.
It explains symptoms
Epithelial thinning, lower moisture, pH change and tissue fragility can make contact, sex or examination uncomfortable.
It avoids over-testing
Objective measures may support assessment, but they are not required for every patient.
It protects safety
Bleeding, ulcers, infection symptoms and atypical lesions need review rather than simple reassurance.
It supports treatment choice
Local tissue treatment, moisturisers, lubricants or referral depend on symptoms, risk factors and preferences.
A whole-context assessment
The useful question is not just whether tissue looks atrophic, but whether the finding explains the patient's symptoms safely.
That is why examination, symptom pattern, menopause history, medication, infection risk and red flags all matter.
Considerations
What to consider
Before deciding what the finding means, consider symptoms, menopause or treatment history, pH or cytology if used, urinary symptoms, bleeding, discharge, pain, skin changes and response to previous treatment.
Consultation priorities
The clinician starts with symptoms, menopause context, medication history, sexual pain, urinary symptoms and bleeding or discharge.
Examination
Tests
Review
History
The clinician starts with symptoms, menopause context, medication history, sexual pain, urinary symptoms and bleeding or discharge.
Examination or tests
Examination may assess colour, moisture, elasticity, friability, pH or cytology where relevant.
Treatment choice
Treatment is matched to symptoms and safety factors rather than to a number alone.
Follow-up
Review checks symptom response and whether new or persistent signs need further investigation.
Practical expectations
Response varies; symptom relief, tissue comfort, examination findings and red flags should be reviewed over time.
Costs, prescription options and treatment suitability should be confirmed directly with the clinic or prescribing clinician before booking.
Common concerns and myths
Common misconceptions
These myths can make vaginal atrophy sound either too simple or unnecessarily frightening.
Myth: a score replaces symptoms
Reality: scores support judgement but the patient's symptoms and safety context still matter.
Myth: pH or VMI is always required
Reality: many GSM diagnoses are clinical, with tests used selectively.
Myth: a cervical smear grades vaginal atrophy
Reality: screening may show atrophic change but is not a full atrophy severity assessment.
Evidence and context
The finding only becomes clinically meaningful when it fits the symptoms, examination and differential diagnosis.
Treatment routes
Options may include non-hormonal moisturisers or lubricants, local vaginal oestrogen, review of medicines, infection testing or specialist referral.
Safety checklist
Safety checklist
Use these checks before assuming a tissue sign is simply atrophy.
Is the symptom pattern clear?
Dryness, burning, entry pain, urinary symptoms, discharge and bleeding should be separated.
Has infection or skin disease been considered?
Viral lesions, thrush, bacterial vaginosis, dermatitis, lichen conditions and trauma can overlap with atrophy signs.
Are red flags absent?
Seek medical advice promptly for postmenopausal bleeding, bleeding after sex, ulcers, unusual discharge, fever, severe pelvic or vulval pain, urinary retention, blood in urine, recurrent infection symptoms or a lesion that does not heal.
Is review planned?
A plan should explain what improvement would look like and when persistent signs need reassessment.
Reassuring signs
Proceeding is more reasonable when symptoms, examination and safety checks all fit a clear GSM pattern.
No red flags
Review plan
Reasons to pause
Seek medical advice promptly for postmenopausal bleeding, bleeding after sex, ulcers, unusual discharge, fever, severe pelvic or vulval pain, urinary retention, blood in urine, recurrent infection symptoms or a lesion that does not heal.
Ulcers
Infection
When to escalate
When to seek medical help
Some vaginal, vulval or urinary symptoms should be assessed promptly.
Use NHS 111 online
Bleeding
Postmenopausal bleeding, bleeding after sex or unexplained bleeding should be assessed by a clinician.
Ulcers or unusual lesions
Ulcers, blisters, a persistent sore area or a lesion that does not heal should not be assumed to be atrophy.
Infection or urinary symptoms
Fever, unusual discharge, blood in urine, urinary retention or recurrent infection symptoms need medical advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain, breathing difficulty or sudden neurological symptoms.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
How objective measures help
Scores and tests can make tissue change easier to describe, but they should be interpreted alongside the patient's symptoms and the clinician's examination.When extra testing may be useful
Extra testing may be considered when symptoms are atypical, recurrent, severe, associated with bleeding or discharge, or not improving as expected.Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware vaginal atrophy information.
NICE NG23 menopause recommendations
NICE gives UK guidance on genitourinary symptoms of menopause, vaginal oestrogen, non-hormonal options and review.
NHS vaginal dryness
NHS explains symptoms, self-care, GP review and bleeding or discharge warning signs.
Genitourinary syndrome of menopause assessment tools
This review explains objective assessment tools such as VHI, VMI and pH in GSM research and practice.
Next step
Book a menopause or vaginal health consultation
A consultation can clarify whether symptoms fit vaginal atrophy, whether another cause needs excluding, and which treatment options are suitable.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 288 curated sources. Additional reviewed material included UK clinical guidance, peer-reviewed clinical papers, evidence reviews, clinical trial records; duplicate and low-relevance records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
